The newly identified 3p21.3 tumour suppressor gene RASSF1A is methylated in the majority of primary lung tumours, lung tumour cell lines and in a variable percentage of breast tumours. To determine the extent of RASSF1A promoter hypermethylation in early lung tumorigenesis, we analysed sputum samples from lung cancer patients and from current and former smokers using a sensitive methylation-specific PCR (MSP) technique. We also analysed RASSF1A promoter region hypermethylation in trios of normal breast/invasive ductal breast carcinoma/ductal carcinoma in situ (DCIS) from breast cancer patients and DCIS without invasive cancer. We found that 50% of small cell lung cancer (SCLC) and 21% of non-small cell lung cancer (NSCLC) patients had RASSF1A methylation, while one of two former smokers and four of 13 current smokers demonstrated RASSF1A methylation in sputum. Furthermore, two of the four current smokers and one former smoker showing RASS-F1A methylation in their sputum developed cancer within 12-14 months of bronchoscopy. In our breast cancer trios, RASSF1A promoter hypermethylation was detected in 65% of invasive cancers, in 42% of corresponding DCIS but in none of the normal breast samples. In addition, we found that three out of 10 DCIS without invasive breast cancer also underwent RASSF1A promoter hypermethylation. Our findings suggest that RASSF1A promoter region hypermethylation may be a useful molecular marker for early detection of lung cancer. Furthermore, since RASSF1A promoter hypermethylation was detected in ductal carcinoma in situ, inactivation of RASSF1A may be an early event in breast tumorigenesis.
Introduction
Lung and breast cancers are among the most common causes of cancer deaths in the Western World. Molecular markers that can detect these cancers at an earlier stage would be very useful, allowing early clinical intervention and improved management. Tumour suppressor gene (TSG) promoter hypermethylation plays an important role in tumorigenesis (Jones and Baylin, 2002) and in some cases can be demonstrated in sputum samples prior to onset of invasive lung cancer (Palmisano et al., 2000) and in precursor lesions of lung and breast carcinomas. Gene promoter hypermethylation potentially provides a noninvasive screen for early cancer detection and offers opportunities to develop novel therapies for reversing methylation.
We and others have recently identified a new 3p21.3 TSG (RASSF1A) from a minimal 120 kb region defined by overlapping homozygous deletions in lung and breast cancers (Dammann et al., 2000; Agathanggelou et al., 2001; Burbee et al., 2001; Lerman and Minna, 2000) . The promoter region of RASSF1A is frequently hypermethylated in a variety of tumour types including lung, breast, kidney and neuroblastoma, nasopharyngeal, gastric, bladder and prostate cancer Byun et al., 2001; Dammann et al., 2001; Lo et al., 2001; Morrissey et al., 2001; Lee et al., 2001; Kuzmin et al., 2002) . RASSF1A promoter hypermethylation is associated with loss of expression in tumour cell lines and expression is restored after treatment with a demethylating agent. Furthermore, in vivo and in vitro studies have demonstrated that RASSF1A suppresses the growth of tumour cell lines (Dammann et al., 2000; Burbee et al., 2001) . These findings establish RASSF1A as a major 3p21.3 TSG.
In order to evaluate RASSF1A promoter hypermethylation for early detection of lung cancer, we determined RASSF1A promoter hypermethylation in sputum samples (obtained at bronchoscopy) from lung cancer patients, heavy smokers (only symptomatic chronic smokers with no evidence of tumour or chronic inflammatory disease on chest radiography were included) and nonsmokers (control). Sputum samples were collected at bronchoscopy, as described in Kersting et al. (2000) . In this study we analysed sputum samples from 32 patients with lung cancer. Eight had small cell lung carcinoma (SCLC) (tumour stage: 4 stage 2, 1 stage 1 and for 3 stage was not known) and 24 had nonsmall cell lung carcinoma (NSCLC) (tumour stage: 1 stage 1, 15 stage 2, 4 stage 3, 3 stage 4 and for one NSCLC stage was not known). We also analysed 13 symptomatic chronic smokers (all heavy smokers of >20 pack-years and suffering from benign lung disease but with no evidence of tumour or chronic inflammatory disease on chest radiography), two ex-smokers and six never smokers. DNA was extracted using a Qiagen Tissue Kit for DNA preparation (Kersting et al., 2000) . We devised a sensitive methylation-specific PCR to detect RASSF1A promoter hypermethylation in these samples (Figure 1a, d) . Hypermethylation of RASSF1A promoter was detected in sputum from four patients with SCLC (50%; n ¼ 8), in five with NSCLC (21%; n ¼ 24), in four chronic smokers (31%; n ¼ 13, >20 pack-years and suffering from benign lung disease), in one of two former smokers and in none of the six never smokers. All methylation-positive PCR products from cancer patients, noncancer smokers and noncancer former smokers were sequenced to make sure that the methylated PCR product was specific. There was no correlation between tumour stage and/or location and RASSF1A methylation status in the lung cancer patient group. The precise risk status for developing lung cancer Hot start PCR was performed using an initial denaturation step at 951C for 15 min followed by 40 cycles of 45 s each at 95, 58 and 721C and a final extension of 10 min at 721C. All PCR reactions were performed using positive and negative controls for both the methylated and unmethylated alleles, selected from a panel of available lung and breast tumour cell lines whose RASSF1A methylation status was previously known ; no-DNA negative controls were also included. PCR products were analysed on 3% ethidium-bromide-stained agarose gels and visualised under UV illumination. MSP products from samples containing methylated alleles were purified using a QIAquick gel extraction kit (Qiagen), ligated into the pGEM-T-Easy plasmid (Promega) and several clones were sequenced: (d) and (e) represent the sequence profiles of a common region of the MSP products (reverse strand) obtained for sputum and breast DCIS samples, respectively; the CpG dinucleotides are underlined and their position in the PCR fragment is indicated.
in chronic and former smokers with RASSF1A sputum methylation remains to be determined. However, to date the ex-smoker with RASSF1A methylation developed lung cancer 1 year after bronchoscopy and has now died. One of the four chronic smokers with RASSF1A methylation developed cancer of the oesophagus occluding the left main bronchus 14 months after the bronchoscopy, while another chronic smoker with RASSF1A methylation, who had larynx carcinoma resected 12 years before, developed metastasising lung cancer 1 year after bronchoscopy and has since died. A recent report described aberrant promoter methylation of p16, MGMT, DAPK and RASSF1A genes in sputum samples from current and former smokers (Belinsky et al., 2002) . RASSF1A methylation was detected in two of 66 sputum samples. The difference in frequencies between our report and those reported by Belinsky et al. might reflect differences between patient populations and/or owing to different MSP primers and conditions used in the two studies. Larger studies are required to determine if RASSF1A promoter region hypermethylation can be used as a molecular marker for early diagnosis of lung cancer.
To determine whether RASSF1A promoter hypermethylation occurs in the early stages of breast cancer development, we performed MSP analysis in a series of trios that included normal breast tissue, invasive ductal breast carcinoma and adjacent ductal carcinoma in situ (DCIS). In all, 20 breast trios made of invasive ductal carcinoma, DCIS preinvasive lesions and collateral morphologically normal breast parenchyma were prepared by microdissection from formalin-fixed, paraffinembedded sections (obtained as in Viacava et al., 1999) and subsequent DNA extraction by proteinase K digestion. Further ten cases of DCIS without associated invasive carcinoma (named 'pure' or 'solitary' DCIS) were also included in the analysis. All microdissections and histopathology were done by PV. Different MSP primers and PCR conditions were used for this part of the study since we found that primers and PCR conditions used for the sputum samples were not optimal for DNA obtained from paraffin-embedded sections.
None of the DNA from normal breast tissue (n ¼ 17) showed RASSF1A methylation, but 11 invasive breast carcinomas (65%; n ¼ 17; eight grade II and nine grade III) and five DCIS (42%; n ¼ 12) demonstrated RASS-F1A methylation (Figure 1b,e) . In 10 cases out of 12, the methylation status of both invasive cancer and DCIS lesions from the same tumour was concordant. There were two tumours where DNA from invasive cancer was positive for RASSF1A methylation, but the corresponding DCIS were negative. These results indicate that RASSF1A hypermethylation generally occurs at least as early as DCIS. In order to investigate whether RASS-F1A promoter hypermethylation is present in DCIS not associated with carcinoma, we analysed 10 DCIS without invasive cancer. Three of 10 (30%) of these cases demonstrated RASSF1A promoter hypermethylation (Figure 1c) . A recent study by Lehmann et al. (2002) developed a sensitive real-time PCR-based assay for quantitative determination of the cell-specific methylation status of genes during breast cancer development. Similar to our data they found no RASSF1A methylation in normal breast epithelium or in lymphocytes from healthy individuals, but could detect RASSF1A methylation in epithelial hyperplasia, papilloma and DCIS. RASSF1A methylation was also detected in low-grade carcinomas and in DCIS without invasive components.
Our results indicate that RASSF1A promoter hypermethylation is a potential molecular marker for the early detection of lung cancer. Furthermore, we demonstrate that RASSF1A methylation occurs at an early stage of breast cancer development, before the advent of invasive carcinoma. These results justify larger follow-up studies to evaluate RASSF1A promoter hypermethylation as a screening tool for early detection of lung cancer and to investigate the relationship between breast cancer and RASSF1A methylation-positive DCIS.
